A detailed history of Silvercrest Asset Management Group LLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 1,091,490 shares of MXCT stock, worth $4.49 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,091,490
Previous 708,163 54.13%
Holding current value
$4.49 Million
Previous $2.78 Million 52.97%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.68 - $5.06 $1.41 Million - $1.94 Million
383,327 Added 54.13%
1,091,490 $4.25 Million
Q2 2024

Aug 14, 2024

SELL
$3.63 - $5.0 $2.57 Million - $3.54 Million
-708,163 Reduced 50.0%
708,163 $2.78 Million
Q2 2024

Aug 14, 2024

BUY
$3.63 - $5.0 $2.6 Million - $3.59 Million
717,237 Added 102.6%
1,416,326 $5.55 Million
Q1 2024

May 15, 2024

BUY
$3.94 - $5.38 $119,023 - $162,524
30,209 Added 4.52%
699,089 $2.93 Million
Q4 2023

Feb 14, 2024

SELL
$2.6 - $5.24 $1.54 Million - $3.1 Million
-591,743 Reduced 46.94%
668,880 $3.14 Million
Q3 2023

Nov 14, 2023

SELL
$3.02 - $5.1 $10,346 - $17,472
-3,426 Reduced 0.27%
1,260,623 $3.93 Million
Q2 2023

Aug 14, 2023

BUY
$3.69 - $5.35 $641,126 - $929,546
173,747 Added 15.94%
1,264,049 $5.8 Million
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $580,569 - $848,525
144,062 Added 15.22%
1,090,302 $5.4 Million
Q4 2022

Feb 14, 2023

SELL
$4.92 - $7.4 $43,837 - $65,934
-8,910 Reduced 0.93%
946,240 $5.17 Million
Q3 2022

Nov 14, 2022

SELL
$4.52 - $6.51 $116,982 - $168,485
-25,881 Reduced 2.64%
955,150 $6.21 Million
Q2 2022

Aug 15, 2022

BUY
$3.59 - $6.81 $1.19 Million - $2.26 Million
332,351 Added 51.23%
981,031 $4.64 Million
Q1 2022

May 16, 2022

BUY
$5.26 - $10.84 $3.41 Million - $7.03 Million
648,680 New
648,680 $4.53 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $418M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.